ArticleTherapeutic advances in neurological disorders2025
Access, satisfaction, adherence and safety to subcutaneous natalizumab compared to intravenous natalizumab in multiple sclerosis in a real-life cohort: first report from Latin America.
Article in Therapeutic advances in neurological disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Patient SAtisfaction with the TYSabri SC Formulation - A Swiss multi-centriC, prospective non-intervenTIONal study: the SATYSFACTION study.Therapeutic advances in neurological disorders · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Subcutaneous natalizumab (scN) was recently approved in Argentina for people with multiple sclerosis (pwMS). The impact of this change in this population is unknown. Objectives: To evaluate the use, access and satisfaction of scN and correlate it with clinical and demographic variables. Desing: cross-sectional study was conducted, surveying pwMS who received scN and ivN from public and private MS Centres since its approval. Methods: Treatment adherence was assessed using the MS Treatment Adherence Questionnaire (MS-TAQ) and satisfaction using Treatment Satisfaction of Questionnaire for Medication (TSQM). Clinical and demographic variables were also recorded. Results: 84 pwMS were included, 58.3% female, mean EDSS: 2.4 ± 1.2, mean age: 34.8 ± 10.8 years, mean disease duration: 7.8 ± 4.5 years, mean time under Conclusion: We found a high rate of change to scN from ivN, associated with a higher score in the comfort and convenience items in people receiving scN, compared to ivN. Access barriers should be addressed in order to improve treatment comfort.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.